Comparison
India or Malaysia? On the categories that matter most, the two countries are not really splitting the work.
Malaysia’s own numbers are real and broad: its government tourism agency names cardiology, oncology, fertility and orthopaedics as its strengths, the same categories this site already documents as India’s core case. So the honest split here is not procedure type. It is cost, fertility regulation, and which country your flight and visa favour.
Malaysia’s medical tourism sector is a real, government-tracked industry: roughly 1.6 million foreign healthcare travellers in 2024, an estimated RM2.72 billion in revenue, and a named set of top specialties, gastroenterology, obstetrics and gynaecology, orthopaedic surgery, oncology, ear-nose-throat treatment and cardiology, with a separate industry-body list adding wellness screening and cosmetic surgery. Malaysia’s own tourism-promotion agency also names four formal Centres of Excellence: oncology, cardiology, fertility, and orthopaedics and pain. Every one of those overlaps with the categories India is already known for on this site: cardiac surgery, cancer treatment, transplant and revision orthopaedics. Unlike Turkey, Thailand, Mexico or South Korea, where this site found a genuine specialisation split with India, Malaysia does not show one. No Malaysian government release we could find breaks its patient volume down by specialty as a percentage, so we can name the categories Malaysia competes in, but not how large each one is.
Where the two countries do separate on real numbers is cost and fertility regulation. Malaysia’s cardiac surgery is commonly quoted at roughly 11,000 to 18,000 US dollars against India’s roughly 4,000 to 6,500 dollars for the same coronary bypass procedure, with reports ranging as low as 7,000 and as high as 25,000 depending on the provider. Even at the lower end of that range the gap is real, roughly two to three times India’s price. Chemotherapy in Malaysia runs roughly two to three times India’s cost. Breast-cancer surgery is the exception: Malaysia’s figure overlaps India’s rather than sitting clearly above it. On fertility, Malaysia’s Medical Council adopted a new guideline in August 2025 stating plainly that gamete and embryo donation for fertilisation is not permissible, and that surrogacy is prohibited, while India’s ART Act permits donor-gamete IVF under registered safeguards, a materially different regulatory posture for anyone who needs donor eggs or sperm, not just a difference in price. Surrogacy is closed to foreign patients in Malaysia, and in India to every foreign national except a couple of Indian origin, who must first obtain a certificate of recommendation from the national Board.
Logistics cut in opposite directions depending on where you are reading this from. For an Australian reader, Malaysia is the closer country: a nonstop flight of roughly six hours from the west coast or eight to nine hours from the east coast, entry with no visa, commonly a 90-day exemption, and only a free digital arrival card, against India’s route, which has no nonstop option at all from the west coast and several longer nonstop options from the east. For a Gulf reader, India is the closer country, roughly three and a half hours nonstop against Malaysia’s roughly seven and a half. An Australian or Gulf citizen still has to arrange a visa on the India side; India has no visa-free arrangement for either group, and whether Malaysia’s general tourist exemption covers a visit made specifically for medical treatment is a question we could not resolve cleanly either way. On scale, we could not find a single verifiable figure for how many Australians or Gulf nationals currently travel to either country. The two hard numbers we found were both narrow: one Gulf country’s Indian consulate issued 364, then 404, then 299 medical visas in 2023, 2024 and 2025 to date, and a dated, unverified industry estimate once put the whole Gulf region at around 8 percent of India’s medical tourists.
Medically reviewed
Reviewed by Dr Gunjan Patel, MBBS, registered with the Gujarat Medical Council (G-65059). Reviewed for accuracy only. This page is general information, not advice about your own case, and Dr Gunjan Patel does not diagnose, prescribe or treat.
How we compared
What five criteria decided this, and our own conflict of interest
So you can disagree with the method rather than just the answer.
- What each country’s inbound patient volume is concentrated in. According to each country’s own government or industry reporting
- What the same procedure costs. When both countries have real pricing data
- Accreditation and oversight. Including where each country’s own data is incomplete
- Fertility-treatment regulation. Where the two countries have taken opposite approaches
- Visa, flight time and language. Checked separately for a reader in Australia and a reader in the Gulf, since the two audiences face different trips
We arrange treatment in India and not in Malaysia, and we are paid a flat fee only when a patient chooses to go ahead with us, never a commission from any hospital. That matters here because this page’s honest finding does not hand India a clean win: on specialisation, Malaysia is a genuine competitor rather than a complement, and on logistics, Malaysia is the better answer for an Australian reader on several counts. Telling you that costs us a possible case, not nothing.
The finding that shapes this page
Malaysia is not a cheaper alternative to a different specialty. It competes for the same ones.
Malaysia Healthcare Travel Council, the government agency responsible for growing this industry, names four formal Specialised Centres of Excellence on its own site: oncology, cardiology, fertility, and orthopaedics and pain. Separately, the same agency’s reporting on 2024 names gastroenterology, obstetrics and gynaecology, orthopaedic surgery, oncology, ear-nose-throat treatment and cardiology as the most sought-after specialties among travellers that year, while an industry body representing Malaysia’s private hospitals names cardiology, orthopaedics, wellness screenings and cosmetic surgery as the highest-demand areas. Those two lists do not fully agree with each other, which itself suggests no single authoritative breakdown exists.
Malaysia Healthcare Travel Council (MHTC), official site, industry overview and centres of excellence pages Checked 2026-09-09.
Fetched live and directly, but rated attributed rather than verified because it is a government tourism-promotion agency’s own promotional material, not an independently audited patient-volume breakdown. No percentage breakdown of patient volume by specialty was found anywhere for Malaysia.
The two named lists overlap on cardiology and orthopaedics but are not identical, itself a signal that no single authoritative percentage breakdown exists publicly.
What they do agree on is the point that matters: cardiology, oncology and orthopaedics appear on every version of Malaysia’s own list, and those are the same categories where India’s inbound volume concentrates. This is unlike South Korea, whose Ministry of Health and Welfare reported roughly three-quarters of its foreign-patient visits in dermatology and cosmetic surgery, or Mexico, whose volume concentrates in dental and standard cosmetic work. Malaysia does not give this comparison a clean specialty split at all. What decides it instead is cost and regulation, covered below.
Comparative analysis of the MHTC and APHM specialty lists against this site’s existing India evidence register Checked 2026-09-09.
This is a synthesis placing two separately-sourced specialty lists side by side, not a single named source stating the comparison directly. No Malaysian or Indian government document directly compares the two countries’ specialty mixes.
~1.6 million travellers, RM2.72bn revenue (2024)
Malaysia's medical tourism industry attracted roughly 1.6 million foreign healthcare travellers in 2024, generating an estimated RM2.72 billion in revenue, reported as 9 percent above the government's own target. The exact year-over-year growth rate is reported inconsistently across sources, between 18 and 21 percent
Malaysia Healthcare Travel Council (MHTC), as relayed by The Sun Malaysia and an independent Malaysian policy-research institute, both citing MHTC as the underlying source Checked 2026-09-09.
MHTC's own site returned an access error on direct fetch, so this is secondary reporting of an MHTC figure, not the primary release.
Malaysia’s five largest reported source markets for 2024 are Indonesia, China, India, Singapore and the United Kingdom. Neither the Gulf nor Australia appears in that list. Malaysia’s forward-looking language describes growing interest from the Middle East as part of a 2030 revenue target, and separate reporting names Qatar, Saudi Arabia and Oman as markets Malaysia’s tourism agency is actively promoting to, not markets it currently reports meaningful volume from. Australia appears only in generic, unranked descriptions of Malaysia’s reach, never with a count. If you are reading this from the Gulf or Australia, neither side of this comparison can currently show you a solid number for how many people like you have already made this trip. The closest either country comes is narrow and dated. 364 (2023), 404 (2024), 299 (2025 to 11 Aug) One Gulf country's Indian consulate reports issuing Medical Visas: 364 in 2023, 404 in 2024, and 299 in 2025 as of 11 August 2025. ~8% Gulf, ~5% UAE (dated industry estimate) The Gulf region is estimated to account for around 8 percent of the total number of medical tourists to India, with the UAE representing 5 percent, according to Naresh Trehan, chairman of India’s Services Export Promotion Council, speaking at a medical-travel conference in the Gulf.
MHTC, as relayed by The Sun and an independent Malaysian policy-research institute Checked 2026-09-09.
A separate, lower-quality secondary compilation names a different top five (Indonesia, China, India, United Kingdom, Japan), which does not fully agree, flagging that even the ranked list is not perfectly consistent across secondary sources.
Channel News Asia reporting via an independent Malaysian policy-research institute’s compiled citation; a separate compilation naming MHTC’s outreach to Qatar, Saudi Arabia and Oman Checked 2026-09-09.
An honest negative finding: the Gulf shows up only as a market Malaysia is trying to grow into, not one it currently reports measured volume from.
Multiple secondary compilations surfaced via search, none traced to a primary MHTC release naming Australia with a figure Checked 2026-09-09.
A second honest negative finding: do not state a current Australia share or count for Malaysia.
Consulate General of India, serving the UAE, official government webpage Checked 2026-09-09.
Real and checkable, but almost certainly undercounts total Gulf-to-India medical travel: covers only the formal Medical Visa category through one consulate’s jurisdiction, and says nothing about other visa types or other Gulf nationalities.
Naresh Trehan, Chairman, Services Export Promotion Council (SEPC), quoted by Gulf News Checked 2026-09-09.
A named industry official’s estimate, not a government dataset; the article’s exact publication date could not be confirmed and context suggests it may be considerably older than current.
Cost
What the same procedure costs
Cardiac surgery shows the widest gap, though not quite as wide as it first looks.
~$11,000-$18,000 (spread $7,000-$25,000)
Malaysia’s private hospital sector commonly quotes coronary artery bypass graft surgery at roughly 11,000 to 18,000 US dollars, with a wider published spread running from about 7,000 up to 25,000 depending on the provider cited, against India’s roughly 4,000 to 6,500 dollars for the same procedure
Compiled from multiple Malaysia-based medical-tourism facilitator pricing pages Checked 2026-09-09.
Self-interested facilitator marketing pricing with a very wide spread, including inconsistent ranges across different pages. Even at the lower end of the commonly quoted range, Malaysia’s cardiac-surgery pricing for a foreign patient runs roughly two to three times India’s; only at the rare 7,000-dollar outlier does the gap nearly close. Both remain well below typical US pricing.
Indian private hospitals commonly price coronary bypass surgery at 4,000 to 6,500 US dollars, inclusive of a 5 to 7 day hospital stay, diagnostics and medication. Both figures remain well below typical US pricing. More on cardiac surgery in India.
Indian private hospital published cardiac surgery pricing Checked 2026-09-09.
Published pricing rather than a survey, and it excludes flights and accommodation. It is a package price quoted in advance, not a record of what patients were finally billed.
Cancer treatment is less uniform. Malaysia’s chemotherapy is commonly quoted at roughly 1,500 to 3,500 dollars per cycle, against India’s lower published range, putting Malaysia at roughly two to three times India’s cost. A chemotherapy cycle at leading private Indian hospitals commonly costs 420 to 1,200 dollars against 10,000 to 50,000 dollars commonly cited in the United States, and breast cancer surgery commonly runs 6,000 to 7,250 dollars in India against 90,000 to 180,000 dollars in the United States. Breast-cancer surgery does not follow the same pattern: Malaysia’s commonly quoted 4,200 to 8,000 dollars overlaps India’s own range rather than sitting clearly above it. The lesson here is that the cost gap is not one flat multiplier across oncology; it depends on which part of the treatment you are pricing. More on cancer care.
Compiled from multiple Malaysia-based cancer-treatment medical-tourism facilitator and provider pricing pages Checked 2026-09-09.
Commercial marketing pricing, not a survey; no government or peer-reviewed Malaysia oncology-cost dataset was found. Against India’s own figure, Malaysia’s cost runs roughly two to three times India’s.
Compiled from cancer-treatment cost comparison and medical-tourism industry pages Checked 2026-09-09.
Wide range, self-interested industry sources, no single government or peer-reviewed survey found for either country. Used only as an order of magnitude, not a quotable price for any individual case.
Compiled from multiple Malaysia-based cancer-treatment medical-tourism facilitator and provider pricing pages Checked 2026-09-09.
Commercial marketing pricing. Unlike chemotherapy, this overlaps India’s existing breast-cancer-surgery range rather than being clearly more expensive; the cost gap between the two countries is not uniform across procedures within oncology.
Fertility treatment sits in the middle. Malaysia’s standard IVF cycle is commonly quoted at roughly 4,200 to 8,000 dollars, more than India’s own range but well below what the same base procedure typically costs in the Gulf. For a patient who can use their own eggs and sperm, that price gap is the main story. For a patient who needs donor eggs or sperm, price is not the deciding factor at all: see the regulation section below.
Compiled from multiple Malaysia-based fertility-clinic and medical-tourism pricing pages Checked 2026-09-09.
Commercial pricing pages, not a survey. This sits between this site’s existing India IVF figure and its UAE IVF figure, cheaper than the Gulf but pricier than India for the same base procedure.
Regulation
Fertility treatment: two very different rulebooks
Malaysia’s Medical Council adopted a new guideline on medically assisted reproduction on 19 August 2025, replacing one dated to 2006.
Malaysia's Medical Council guideline on medically assisted reproduction, second edition, formally adopted 19 August 2025, states that gamete and embryo donation for fertilisation 'is not permissible and prohibited in accordance with the National ART Policy,' and that surrogacy 'is prohibited by the National ART Policy'
Malaysian Medical Council, guideline on medically assisted reproduction, second edition (V2/2025), sections 5 and 9 Checked 2026-09-09.
Read directly from the primary government-regulatory-body PDF and personally confirmed word for word during this page’s fact-check. Materially more restrictive than India’s ART Act 2021, which permits donor-gamete IVF under specific registered safeguards rather than banning it outright.
The same guideline states that medically assisted reproduction should only be offered to legally married couples, reflecting what it describes as a widely held societal belief in Malaysia. India’s ART Act of 2021 takes the opposite approach on donation specifically: it permits donor-gamete IVF and ICSI, but only through registered independent gamete banks, under a one-donor-to-one-couple rule and mandatory donor insurance, while also restricting eligibility to an infertile married couple. More on fertility treatment in India.
Malaysian Medical Council, guideline on medically assisted reproduction, second edition (V2/2025), section 2 Checked 2026-09-09.
Read directly from the primary guideline PDF and personally confirmed during this page’s fact-check. Functionally similar in effect to India’s ART Act restricting eligibility to an infertile married couple, though Malaysia’s rule is a professional-council guideline rather than a Parliamentary Act, a different and more easily changed kind of instrument.
Surrogacy sits under a separate Indian law, and that law is closed to most foreign patients. India’s Surrogacy (Regulation) Act 2021 defines a couple as a legally married Indian man and woman, and an intending woman as an Indian widow or divorcee aged 35 to 45; the only other route it names is for a couple of Indian origin, who must first obtain a certificate of recommendation from the national Board, so a foreign national with no Indian origin has no route to surrogacy in India.
Surrogacy (Regulation) Act 2021 (Act No. 47 of 2021), section 2(1)(h), section 2(1)(s) and the proviso to section 4(ii)(a), Gazette of India Extraordinary No. 64, 25 December 2021 Checked 2026-10-03.
Read on 3 October 2026 from a government-hosted copy of the gazetted Act. The Act does not itself define a couple of Indian origin; secondary legal reporting says the amended Surrogacy Rules treat it as a couple who are both Overseas Citizens of India, which we have not confirmed from the Rules text. Surrogacy is governed by this Act, separately from the Assisted Reproductive Technology (Regulation) Act 2021 that covers donor-egg and donor-sperm IVF. Not legal advice.
Malaysia has no standalone Parliamentary Act governing this area at all. Malaysia has no standalone Assisted Reproductive Technology statute passed by its Parliament; a draft Act has reportedly been discussed since at least 2009 but has not been enacted, leaving the field governed only by the Medical Council's professional guideline, health-ministry laboratory standards, and, for Muslims, religious-authority rulings. A named bioethicist has reported, describing conduct under the earlier 2006 guideline rather than the new one, that commercial egg-donation trading continued at private Malaysian clinics serving foreign and non-Muslim patients, describing unregulated donor agents and at least one alleged case of donor substitution without a patient’s knowledge. This is one academic’s advocacy commentary from before the 2025 ban took effect, not a peer-reviewed study or a regulator’s own enforcement data on the new rule, so treat it as a reported historical concern rather than evidence of how the current guideline is being enforced.
Compiled from secondary legal-commentary and medical-tourism-industry summaries discussing Malaysia’s ART regulatory landscape Checked 2026-09-09.
A primary Malaysian parliamentary record confirming the draft Act’s status could not be located; rests on secondary legal and industry commentary. If accurate, Malaysia’s fertility-sector rules carry less legal weight and less consistent enforcement than India’s ART Act.
Dr Alexis Heng Boon Chin, opinion and commentary via CodeBlue, a Malaysian health-policy news outlet Checked 2026-09-09.
This is one named academic’s repeated opinion and advocacy commentary from before the 2025 ban took effect, not a peer-reviewed study, government audit, or regulator’s enforcement data on the current rule. State it as a historical reported concern, not evidence of how the new guideline is being enforced.
Oversight
Accreditation, and a transparency gap in both countries
On international accreditation, the two countries are not close. ~12-16 (Malaysia) vs ~40-47 (India), compiled estimate A secondary compilation states Malaysia has approximately 12 to 16 JCI-accredited hospitals and facilities, commonly cited as about 16. Both India and Turkey have broadly comparable numbers of JCI accredited hospitals, in the region of 40 to 50 each, and India additionally has several hundred hospitals accredited under the national NABH scheme. Malaysia’s own domestic scheme had accredited 123 hospitals and facilities as of December 2024, a smaller domestic footprint than the several hundred NABH-accredited facilities already documented for India on this site.
Medical Tourism Watch, 'Top 20 Countries With the Most JCI-Accredited Hospitals' Checked 2026-09-09.
A secondary compilation, not the accrediting body’s own directory, which returned an access error on direct fetch. Published counts change as accreditations lapse and renew; on JCI accreditation specifically, Malaysia is not close to parity with India.
JCI directory and industry compilations Checked 2026-08-25.
Published counts differ between sources and change as accreditations lapse and renew. We give a range rather than a number for that reason, and treat accreditation as a floor rather than a ranking.
PR Newswire release on the accreditation body’s international training-programme accreditation, cross-checked against a Malaysian business-press outlet Checked 2026-09-09.
Read via a press release rather than the accrediting body’s own primary published register. At 123 facilities this domestic scheme is far smaller in scale than the several hundred NABH-accredited facilities already documented for India.
Neither country gave us anything comparable to the CDC-tracked outbreaks this site documents for Mexico or the peer-reviewed forensic mortality study documented for South Korea. We looked specifically for a Malaysia equivalent and did not find one. What we did find is different, but real: a peer-reviewed 2014 review of Malaysia’s malpractice tort system states plainly that comprehensive annual statistics on medical negligence claims are not collected systematically in Malaysia, while citing Ministry of Health figures showing claims against government doctors rising between the late 1980s and early 1990s, then rising further between 2006 and 2011.
Absence noted after multiple targeted searches of CDC materials and peer-reviewed literature databases Checked 2026-09-09.
An honest report of absence, not proof that no such incident exists, only that none could be found via this research. Unlike Mexico’s CDC-tracked outbreaks or South Korea’s peer-reviewed forensic mortality study, Malaysia does not currently have a comparable documented, checkable outbreak or mortality study.
Hambali, S.N. and Khodapanahandeh, S., 'A Review of Medical Malpractice Issues in Malaysia under Tort Litigation System,' Global Journal of Health Science, 2014, 6(4):76-83 Checked 2026-09-09.
Covers Malaysia’s domestic tort system in general, not foreign medical-tourism patients specifically, and does not discuss medical tourism at all. The honest takeaway is that Malaysia does not systematically track its own malpractice-claim statistics, a real transparency gap.
A separate peer-reviewed 2016 paper on Malaysian patient safety ties the country’s medical-tourism strategy directly to private-hospital quality gaps, noting private-hospital nurses performed worse than public-hospital nurses in a national audit and that complaints to the health ministry’s medico-legal section, and associated compensation costs, were both rising. There is also a documented, current enforcement problem specific to unlicensed operators. Malaysia's Ministry of Health stated in July 2024 it would take legal action against unlicensed foreign nationals running uncertified aesthetic medical service centres, following a patient's breast-surgery complications; in March 2025 Malaysia's Immigration Department, working with a state health department, raided two unlicensed cosmetic-surgery clinics run by foreign nationals. These are enforcement actions against operators outside the accredited hospital system MHTC promotes to medical tourists, not findings about that accredited system itself, but they are a genuine, government-acknowledged gap worth knowing about before choosing a provider in either country. What happens if something goes wrong.
Global Journal of Health Science, October 2016, Vol. 8 No. 6 Checked 2026-09-09.
Peer-reviewed and directly relevant to the medical-tourism-serving private sector, but a general quality and safety-systems paper, not a mortality or outbreak study. The specific complaint-cost estimate cited within the paper is itself described as an estimate, not an audited total.
News reporting on a Ministry of Health statement, July 2024, and a separate immigration enforcement action, March 2025 Checked 2026-09-09.
Read via search-indexed extracts after direct fetch attempts returned an access error. Genuine, government-acknowledged enforcement actions against unlicensed, illegally operating practitioners outside the accredited hospital system, not against the accredited hospitals themselves.
If you are flying from the Gulf, or from Australia
Visa and flight time point in opposite directions.
Entry to Malaysia is straightforward for an Australian reader.
90-day visa-free entry
Australian citizens do not need a visa to enter Malaysia for a short visit; Malaysia's Immigration Department lists Australia among countries exempt from visa requirements, with a stay length commonly reported at 90 days
Malaysian Immigration Department, visa requirement by country page, cross-checked against secondary travel-insurer and encyclopedia guides for the stay-length figure Checked 2026-09-09.
The exemption for Australia is confirmed directly on the primary government page; the specific 90-day stay-length figure did not render in extractable text from that page and is taken from consistent secondary sources instead.
For a Gulf reader the picture is less certain: 90 days (disputed for medical purpose) Citizens of the UAE and other Gulf Cooperation Council states are commonly reported to receive 90-day visa-free entry to Malaysia for general tourism, the same exemption given to Australia, the UK, the EU, Japan and Canada; whether this general exemption also covers a visit made specifically for medical treatment, or whether a separate medical eVisa category applies instead, could not be resolved against one authoritative source. Both groups still need Malaysia’s free Digital Arrival Card, submitted online up to three days ahead, a short administrative step rather than a visa application, once entry itself is settled. Malaysia requires the free, mandatory Malaysia Digital Arrival Card from most foreign visitors since 1 January 2024, submitted online up to three days before arrival, a short administrative step rather than a visa. India, by contrast, requires a medical visa or e-Medical visa for treatment, for both audiences. India requires a medical visa or e-Medical visa for entry for the purpose of treatment, and grants no visa-free arrangement to Australian citizens or to the citizens of any Gulf state.
A general reference on Malaysia’s visa policy, cross-checked against a Malaysian consular requirement page and commercial visa-guide sites Checked 2026-09-09.
Malaysia’s Immigration Department country-list page did not show the UAE explicitly in the extract available in this research, a technical limitation rather than evidence of exclusion. A secondary guide separately lists a medical eVisa category for at least one Gulf nationality, raising a real, unresolved question about whether the general tourist exemption applies to medical travel specifically.
Malaysian Immigration Department portal information, corroborated by multiple independent travel-guide sources Checked 2026-09-09.
Read via search-indexed sources rather than the Immigration Department’s own portal page directly.
This site’s existing evidence register, corroborated against secondary visa-guide sources describing India’s visa-exemption list Checked 2026-09-09.
Applies to Australian and Gulf-country citizens only. India does let some neighbouring countries’ citizens enter without a visa, so this is not a rule for every nationality. Not immigration advice.
Flight time is where the two audiences diverge.
~6h nonstop (west); ~8-9h nonstop (east)
Nonstop flight time between Malaysia and Australia runs roughly 6 hours from Malaysia’s west-coast-facing Australian route and roughly 8 to 9 hours from Australia’s east coast, operated by multiple carriers
Compiled from flight-time aggregator data Checked 2026-09-09.
Aggregator-compiled planning figure, matching this site’s existing convention for flight-time entries. Airline schedules change; confirm before publishing a fixed number.
No nonstop from the west coast; several nonstop routes from the east, ~11h45m-13h There is no nonstop flight from Australia’s west coast to India; the fastest available itinerary runs through a connecting hub at roughly 11 to 12.5 hours end to end. From Australia’s east coast, several nonstop routes currently operate, run by two airlines, at roughly 11 hours 45 minutes to just under 13 hours. A Gulf reader is closer to India: the nonstop flight from the Gulf to India takes about 3 to 4.5 hours depending on the Indian city, against roughly 7 hours 25 minutes to Malaysia, so India is the closer of the two by roughly three to four hours each way, the reverse of the Australia comparison, where Malaysia is the closer country. Neither of us can change geography, so read whichever of those two facts applies to you and weigh it honestly against everything above.
Compiled from flight-time aggregator and airline route data Checked 2026-09-25.
Confirmed nonstop east-coast routes include services from two airlines, and one of those services is seasonal; schedules change and should be confirmed before booking. The India or Malaysia page uses the comparison that Malaysia is reachable nonstop in roughly 6 to 9 hours from Australia, meaningfully shorter than every one of these India routes.
Compiled from flight-time aggregator data Checked 2026-09-09.
Aggregator-compiled planning figure, matching this site’s existing flight-time entries for other countries.
This site’s Gulf-to-India flight-time entry, compared against this research’s Gulf-Malaysia figure Checked 2026-09-26.
Flight-time logistics cut in opposite directions for the two audiences this page targets: Malaysia is closer for an Australian reader, India is closer for a Gulf or UAE reader.
On language, Malaysia’s private, internationally accredited hospital tier operates in English as a working language, a legacy of British colonial rule that still shapes MBBS medical education there. English remains the language of instruction for MBBS medical degrees at Malaysian universities, including private medical schools running formal partnership programmes with UK universities, a legacy of Malaysia’s history as a British colonial territory. That is a genuine strength, but it is not proven uniform across Malaysia’s whole medical system. The chairman of Malaysia's Medical Deans Council of Public Universities stated publicly that poor English proficiency is visible not only among medical undergraduates but also among young doctors in hospital presentations and peer discussion, noting more than 90 percent of medical journals are published in English. ~1,000 medical graduates (2015 report) In 2015 the president of a state branch of the Malaysian Medical Association was quoted saying that around 1,000 medical graduates who had completed their public-hospital housemanship abandoned the medical profession, citing poor English as the main reason among other factors. Both concerns are about the domestic public-hospital housemanship system, not the private tier that treats foreign patients, so the honest summary is that Malaysia’s English strength is concentrated where medical tourists go, not proven across the whole system the way India’s national English-medium MBBS curriculum already is.
University programme pages and secondary academic writing on colonial-era medical education in Malaya Checked 2026-09-09.
Compiled from university marketing pages and secondary historical scholarship rather than a single peer-reviewed or government-issued statement of national policy.
The Edge Malaysia, reporting the Medical Deans Council of Public Universities chairman Checked 2026-09-09.
A named professional body’s chairman quoted in a business newspaper, not a peer-reviewed study or government audit of practising physicians’ English; a precise publication year could not be established.
Malaysiakini, 9 November 2015, quoting the president of a state branch of the Malaysian Medical Association Checked 2026-09-09.
A named, dated (2015) local-branch officer’s account relayed by one newspaper, concerning newly qualified doctors in the domestic public system, not the private, foreign-patient-facing hospital sector specifically.
One more honest gap for both audiences: Australia’s own government travel-advice site states there is no agreement between Australia and Malaysia for free healthcare, and that travellers must pay for all medical care in Malaysia, including hospital stays or evacuation, making comprehensive travel insurance necessary. No formal Gulf-country-to-Malaysia government health-cooperation or reciprocal-insurance agreement was found; what exists instead is promotional activity, including a Malaysia Healthcare Travel Council trade and health-expo event in the Gulf in 2025 aimed at growing patient flow from Gulf states. Neither of these gaps is unique to Malaysia. The same absence exists for India.
Smartraveller, the Australian Government’s official travel advisory site, Malaysia page Checked 2026-09-09.
Every attempt to fetch this page directly in this research timed out; read via a search-engine synthesis of the page’s own wording rather than the page itself.
Search-indexed trade-press coverage of MHTC’s Gulf-region promotional activity Checked 2026-09-09.
An honest "we looked and did not find a comparable reciprocal agreement" finding, not a claim that no cooperation of any kind exists.
Where Malaysia has a real edge
For an Australian reader, getting there is simply easier.
Sized honestly, Malaysia’s clearest advantage in this comparison is not a specialty or a price. It is logistics for an Australian reader: a shorter flight with a nonstop option from both coasts, visa-free entry, and a light administrative arrival process, against India’s longer flight from the west coast, no nonstop option there at all, and a mandatory medical visa. If travel comfort and total trip length matter more to you than the price difference documented above, that is a real, defensible reason to choose Malaysia, and we will say so plainly rather than argue you out of it.
Malaysia’s sector is also large and growing, by its own reporting 9 percent above its own government’s 2024 target, though the exact year-over-year growth rate is reported inconsistently across the sources we found, between 18 and 21 percent. MHTC is targeting RM12 billion in healthcare-travel revenue by 2030, a figure separately reported elsewhere as a US$2.7 billion annual target for the same era; separately, Malaysia’s Ministry of Health describes the country’s whole healthcare sector, not medical-tourism patients specifically, as supporting more than 300,000 direct and indirect jobs. That scale is real. It does not, on the sources we could verify, translate into a documented cost advantage over India, or into more permissive rules on donor eggs and sperm, or into a larger current patient flow from the Gulf or Australia specifically. On cost and on access to donor eggs and sperm, the evidence favours India; on patient volume from your own region, we found no figure that settles it either way.
MHTC’s stated target, as relayed by Focus Malaysia and Channel News Asia reporting, both cited secondhand via an independent Malaysian policy-research institute; a Ministry of Health Malaysia (2024) jobs figure cited in the same compilation Checked 2026-09-09.
A growth target, not a current-year figure; neither underlying article could be fetched directly. The jobs figure is a whole-of-sector employment number, not specific to foreign or medical-tourism patients.
Summary
Side by side.
| Criterion | India | Malaysia |
|---|---|---|
| Strongest in | Cardiac surgery, cancer treatment, transplant, revision orthopaedics | Same broad list, plus fertility; no single narrow niche, and no published percentage breakdown |
| Entry requirement | Medical visa or e-Medical visa required; no visa-free route for Australian or Gulf citizens | Visa-free entry, commonly 90 days, for Australian and most Gulf citizens, plus a free digital arrival card |
| Typical flight from the Gulf | Roughly 3 hours 25 to 30 minutes nonstop | Roughly 7 hours 25 minutes nonstop |
| Typical flight from Australia | No nonstop from the west coast; several nonstop routes from the east, roughly 11 hours 45 minutes to 13 hours | Roughly 6 hours nonstop from the west coast; 8 to 9 hours nonstop from the east |
| Accreditation (compiled estimates) | Roughly 40 to 47 JCI-accredited facilities; several hundred NABH-accredited facilities | Roughly 12 to 16 JCI-accredited facilities; 123 domestically accredited facilities as of December 2024 |
| Representative cost line (cardiac bypass) | Commonly quoted $4,000 to $6,500 | Commonly quoted $11,000 to $18,000, spread as wide as $7,000 to $25,000 |
| Fertility regulation | ART Act 2021 permits regulated donor-gamete IVF through registered gamete banks; surrogacy limited by a separate Act to Indian couples, Indian widows or divorcees, and couples of Indian origin with a Board certificate | 2025 Medical Council guideline prohibits donor gametes and surrogacy outright |
| Current measured patient volume from the Gulf or Australia | No total figure found; one narrow verified figure exists (one Gulf country’s consulate: 364, 404 and 299 medical visas, 2023 to 2025) | No figure found for either audience; both appear only in generic lists or 2030 growth language |
Questions
What people ask when choosing between them.
Malaysia's own government agency names cardiology, oncology, fertility and orthopaedics as its strengths. Isn't that the same list as India's?
Largely, yes, and we are not going to pretend otherwise. Malaysia Healthcare Travel Council names those four as its formal centres of excellence, and its 2024 reporting adds gastroenterology, obstetrics and gynaecology and ear-nose-throat treatment to the list of top specialties that year. All of those overlap with the categories this site documents as India’s own core strengths. No Malaysian source we found gives a percentage breakdown of patient volume by specialty, so we cannot tell you which country does more of any one thing. What we can tell you, on the numbers we could verify, is that cost and fertility-treatment regulation are where the two countries differ, not the specialty itself.
Is IVF cheaper in Malaysia or India?
India, on the pricing we could verify. Malaysia’s standard IVF cycle is commonly quoted at roughly 4,200 to 8,000 US dollars, above India’s own range but below typical Gulf pricing for the same base procedure. Price is not the only question, though. Malaysia’s Medical Council adopted a guideline on 19 August 2025 that prohibits donor-egg and donor-sperm treatment and surrogacy outright. India’s ART Act permits donor-gamete IVF through registered gamete banks under specific safeguards. If your treatment plan depends on donor eggs or sperm, that regulatory difference matters more than the price gap. Surrogacy is not open to foreign patients in India either, unless they are a couple of Indian origin who obtain a certificate of recommendation from the national Board.
Is Malaysia safe for medical treatment?
We did not find anything comparable to the documented outbreaks or mortality studies this site cites for some other countries, and we are not going to invent one to force a parallel. What we did find is real, though different in kind: a peer-reviewed 2014 study found that Malaysia does not systematically track its own medical negligence claim statistics, a 2016 peer-reviewed paper found private-hospital nurses performing worse than public-hospital nurses in a national audit alongside rising complaint numbers, and Malaysia’s Ministry of Health and immigration authorities have taken repeated, documented enforcement action against unlicensed foreign-run cosmetic clinics in 2024 and 2025. Those enforcement actions targeted operators outside the accredited hospital system that markets to medical tourists, not that system itself.
You arrange treatment in India. Why would you recommend Malaysia?
Because we are paid a flat fee only when a patient chooses to go ahead with us, not a commission from any hospital, in India or anywhere else. Telling an Australian reader that Malaysia beats India on flight time, visa and arrival process costs us a possible case, not nothing, and we would rather say it than argue you into a plane ticket that serves our own fee instead of your actual priorities. On this comparison, an Australian reader gets a shorter, simpler trip to Malaysia: a nonstop flight, no visa, and a light arrival process, against India’s longer flight and mandatory medical visa. If that matters more to you than the cost and fertility-regulation differences documented above, Malaysia is a defensible choice.
What about Turkey, Thailand, Mexico or South Korea?
Each of those comparisons found a cleaner split than this one. India or Turkey and India or Thailand both sit closer to a genuine specialisation divide with India, weighted toward European travel patterns. India or Mexico is the practical default for an American patient’s dental, cosmetic and much of their weight-loss surgery. India or South Korea’s own government data shows its foreign-patient volume concentrated in dermatology and cosmetic work rather than the complex cases that usually bring someone to look at India. Malaysia is the outlier in this series: it competes with India directly across several of the same categories, and the honest answer here turns on cost and regulation rather than on what each country specialises in.
Weighing a longer-established comparison too? India or Turkey resolves on a much cleaner specialisation split, for a reader flying from Europe instead of Australia or the Gulf.
Work out which country fits your case, before you compare prices.
Thirty minutes, free. If the numbers point you toward Malaysia instead, on cost, regulation or your own flight time, we will tell you that plainly.